Get the Stockscreener App
22.66
6.60%
-1.725
Anaptysbio Inc stock is traded at $22.66, with a volume of 146.68K.
It is down -6.60% in the last 24 hours and up +5.03% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$24.38
Open:
$25.16
24h Volume:
146.68K
Relative Volume:
0.36
Market Cap:
$698.64M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-4.3651
EPS:
-5.19
Net Cash Flow:
$-121.61M
1W Performance:
-9.82%
1M Performance:
+5.03%
6M Performance:
-2.98%
1Y Performance:
+51.80%
1-Day Range:
$22.58
$25.16
1-Week Range:
$22.35
$26.51
52-Week Range:
$14.70
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
22.58 | 698.64M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.88 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.83 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.19 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.42 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Key Takeaways From AnaptysBio Analyst Ratings - Benzinga
AnaptysBio (NASDAQ:ANAB) Downgraded by BTIG Research to Neutral - MarketBeat
BTIG cuts AnaptysBio shares to neutral on high-risk trial setup - Investing.com UK
163,997 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Acquired by Walleye Capital LLC - MarketBeat
How to Take Advantage of moves in (ANAB) - Stock Traders Daily
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Jennison Associates LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Victory Capital Management Inc. Boosts Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching - Seeking Alpha
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) - MSN
Truist maintains hold on AnaptysBio with $30 target By Investing.com - Investing.com UK
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $54.64 - MarketBeat
AnaptysBio’s (ANAB) “Outperform” Rating Reiterated at Wedbush - Defense World
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - Yahoo Finance
JPMorgan Chase & Co. Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
(ANAB) Proactive Strategies - Stock Traders Daily
Leerink Partnrs Lifts Earnings Estimates for AnaptysBio - Defense World
What is Wedbush’s Forecast for AnaptysBio FY2024 Earnings? - Defense World
FY2024 EPS Estimates for AnaptysBio Lifted by HC Wainwright - Defense World
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Forecasts Higher Earnings for AnaptysBio - MarketBeat
HC Wainwright Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Earns “Outperform” Rating from Wedbush - Defense World
Lilly bid wilts as others forge on with PD-1 in RA - BioWorld Online
AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet - Simply Wall St
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - Defense World
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates - MSN
AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Earnings Beat - MarketBeat
AnaptysBio shares hold Outperform rating; Leerink notes strong cash position and clinical progress - Investing.com UK
AnaptysBio stock target cut on increased expenses By Investing.com - Investing.com Canada
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright - StreetInsider.com
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners - StreetInsider.com
AnaptysBio Inc (ANAB) Q3 2024 Earnings: Revenue Soars to $30M, E - GuruFocus.com
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
AnaptysBio Reports Q3 2024 Financial Results and Updates - TipRanks
AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c - StreetInsider.com
Anaptys Announces Participation in November and December Investor Conferences - The Manila Times
AnaptysBio's Q3 Revenue Surges to $30M, Cash Position Hits $458M Ahead of Key Trial Data | ANAB Stock News - StockTitan
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4%Here's What Happened - MarketBeat
Things To Consider Before Buying AnaptysBio Inc (NASDAQ: ANAB) - Stocks Register
AnaptysBio: Too Risky, Especially After LLY Drops Its Related Programs - Seeking Alpha
AnaptysBio (ANAB) Shares Plunge as Eli Lilly Ends Arthritis Drug Research - GuruFocus.com
AnaptysBio (NASDAQ:ANAB) Given "Buy" Rating at HC Wainwright - MarketBeat
(ANAB) Trading Advice - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Gap DownHere's What Happened - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $33.00 - MarketBeat
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline - XM
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lizzul Paul F. | Chief Medical Officer |
Sep 23 '24 |
Option Exercise |
18.50 |
1,500 |
27,750 |
16,898 |
| Lizzul Paul F. | Chief Medical Officer |
Sep 23 '24 |
Sale |
38.67 |
1,500 |
58,005 |
15,398 |
1.05%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):